Latest News for: blind placebo

Edit

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Pharmiweb 25 Mar 2025
United Biotechnology recently completed a randomized, double-blind, placebo-controlled phase 1b trial in China designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ...
Edit

Asthma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, ...

GetNews 25 Mar 2025
In March 2025, Amgen organized a phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma.
Edit

Neurofibromatosis Type 2 Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight ...

GetNews 24 Mar 2025
This global, randomized, double-blind, placebo-controlled multicenter study is the largest of its kind in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN).
Edit

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Canoe 24 Mar 2025
PMN310 has successfully completed a Phase 1a clinical study (NCT06105528), a double-blind, placebo-controlled, single ascending dose study of the safety, tolerability and pharmacokinetics of PMN310 infusions in healthy volunteers.Advertisement 7 ... Tel.
Edit

Study finds microdosing LSD is not effective in reducing ADHD symptoms

PsyPost 23 Mar 2025
A new clinical trial has found that taking low doses of LSD twice a week does not reduce symptoms of attention-deficit/hyperactivity disorder in adults more than a placebo ... This highlights the need for a well-blinded placebo control group.”.
Edit

Life in the old dog yet: how biotech firms are looking to extend the lives of our pets

The Observer 23 Mar 2025
Last November, my family brought home a puppy ... Learn more ... They’ve prescribed rapamycin to thousands of pet dogs in double-blind, placebo- controlled trials – tracking their health progress through annual questionnaires (or in some cases, DNA testing).
Edit

Liver Cirrhosis Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight ...

GetNews 21 Mar 2025
Some of the key takeaways from the Liver Cirrhosis Pipeline Report. ... This placebo-controlled, multicenter, double-blind, dose-ranging, randomized trial focused on individuals with the condition ... Liver Cirrhosis Overview ... PHIN-214. PharmaIN. GXHPC1 ... NA ... 1 ... 2.
Edit

Sickle Cell Disease Pipeline 2025 Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | ...

GetNews 21 Mar 2025
This Phase IIa, double-blind, randomized, placebo-controlled, parallel, multi-center proof-of-concept study will be co-funded and co-monitored by INTENT, the Indian National Clinical Trial and ...
Edit

Schizophrenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, ...

GetNews 20 Mar 2025
June 2024.- AbbVie- A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, With an Additional 18-Week Blinded Extension Period.
Edit

Guestwords: Never Brush Again

The East Hampton Star 20 Mar 2025
Placebo tests and double-blind studies are being conducted by Moderna and Pfizer, the two major producers of Covid vaccines, to determine how a little white pill can create a condition where one pill will possibly herald the end of human agency ... .
Edit

Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the Clinic

Pharmiweb 20 Mar 2025
... scientists, and regulatory experts, Infinitopes is poised to initiate its vaccine candidate, ITOP1, in a highly anticipated double-blind, randomised, placebo-controlled Phase I/IIa clinical trial.
Edit

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

ACCESSWIRE 20 Mar 2025
IGC-AD1 is IGC Pharma's investigational cannabinoid-based therapy currently in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study (CALMA) evaluating its safety and efficacy for treating agitation in Alzheimer's dementia ... ... ....
Edit

Traumatic Brain Injury Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approval, Medication, Epidemiology, Therapies ...

GetNews 20 Mar 2025
In February 2025, Merz Pharmaceuticals GmbH announced results of a Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the ...
Edit

Cannabis intoxication alters metabolism, but frequent users show fewer effects

PsyPost 19 Mar 2025
Participants took part in a double-blind, placebo-controlled experiment where they inhaled vaporized cannabis containing THC (the primary psychoactive compound in cannabis) on one test day and a placebo on another test day.
Edit

Anti-amyloid therapy may keep Alzheimer’s symptoms at bay in certain patients, study suggests

CNN 19 Mar 2025
... therapies, compared with a placebo ... Study participants who took gantenerumab during either the double-blind, placebo-controlled portion of the study or only in the open extension had a modest benefit.
×